Herbs (Global Traditional) · European
Pulsatilla (Pulsatilla vulgaris) (Pulsatilla vulgaris)
Moderate Evidencebotanical3 PubMed Studies
Hermetica Superfood Encyclopedia
Pulsatilla vulgaris contains bioactive compound AB4 that inhibits inflammatory pathways through NF-κB suppression. Research demonstrates anti-inflammatory and anticancer properties, though clinical evidence remains limited.
Pulsatilla vulgaris, commonly known as pasqueflower, is a perennial flowering herb native to Europe and parts of Asia, belonging to the Ranunculaceae family. It is sourced primarily from the roots, which are harvested, dried, and prepared via decoction or methanolic extraction for traditional medicine and pharmacological studies.
No human clinical trials, RCTs, or meta-analyses were identified for Pulsatilla vulgaris; evidence is limited to preclinical in vitro and animal studies. In vitro cancer studies showed methanolic root extracts inhibited multiple signaling pathways at 40-300 µg/mL, while animal models demonstrated anti-inflammatory effects of AB4 at 12.5-50 mg/kg doses.
No clinically studied human dosage ranges are available. Animal studies used AB4 at 12.5-50 mg/kg orally for anti-inflammatory effects. In vitro cancer studies used root extracts at 40-300 µg/mL. Traditional preparations use powdered root or decoctions without standardized dosing. Consult a healthcare provider before starting any new supplement.
Pulsatilla vulgaris is a medicinal herb, not a food ingredient, so conventional macronutrient/micronutrient profiling is not applicable in the traditional dietary sense. Its biological activity is driven primarily by bioactive secondary metabolites rather than nutritional content. Key documented bioactive compounds include: Anemonin and protoanemonin (lactone glycosides) — the principal bioactive constituents, with protoanemonin being the toxic precursor that converts to the less toxic anemonin upon drying; Triterpenoid saponins including hederagenin and oleanolic acid derivatives — the polysaccharide fraction AB4 (tested at 12.5–50 mg/kg in animal studies) is responsible for documented anti-inflammatory effects via NF-κB pathway inhibition; Flavonoids including luteolin and quercetin glycosides — present in aerial parts at low concentrations (estimated <0.5% dry weight, specific concentrations not well-characterized in literature); Ranunculin — a glucoside precursor to protoanemonin, enzymatically converted upon plant cell damage; Phytosterols including beta-sitosterol — detected in root extracts; Tannins and phenolic acids — present in aerial parts contributing to antibacterial properties documented in preliminary studies. Fiber, protein, and standard micronutrient (vitamin/mineral) content are not characterized in peer-reviewed literature, as the plant is used exclusively in medicinal/homeopathic contexts at sub-gram doses, not as a food source. Bioavailability note: Protoanemonin is highly volatile and unstable; dried preparations significantly reduce toxicity. Oral bioavailability of saponin fractions is considered low without formulation optimization.
Pulsatilla's bioactive compound AB4 suppresses inflammation by inhibiting the NF-κB signaling pathway, which controls inflammatory cytokine production. In vitro studies show it targets 12 cancer-related signaling pathways in cervical cancer cells. The compound appears to modulate immune responses and cellular proliferation through multiple molecular targets.
Animal studies using AB4 extract (12.5-50 mg/kg) demonstrated significant reduction in xylene-induced ear edema and LPS-induced organ damage. In vitro research on HeLa cervical cancer cells showed inhibition of multiple cancer pathways. However, no human clinical trials have been conducted to confirm these effects. Current evidence is limited to preliminary laboratory and animal studies.
Fresh pulsatilla plant contains protoanemonin, which can cause skin irritation and mucous membrane inflammation. Pregnancy and breastfeeding safety is unknown due to lack of clinical data. Potential interactions with anticoagulant medications due to possible bleeding effects. Standardized dosing guidelines have not been established for human use.
